Company Description
Tempest Therapeutics, Inc., a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various cancers.
The company’s two clinical programs Amezalpat formerly PST-1120, an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha, which is in Phase III; and TPST-1495, a novel, small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, which is in Phase II.
The company has agreement with Roche to advance the evaluation of amezalpat (TPST-1120) in combination with atezolizumab (Tecentriq) and bevacizumab.
Tempest Therapeutics, Inc. was incorporated in 2011 and is headquartered in Brisbane, California. Tempest Therapeutics, Inc. operates as a subsidiary of Inception Sciences, Inc.
| Country | United States |
| Founded | 2011 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 24 |
| CEO | Stephen Brady |
Contact Details
Address: 2000 Sierra Point Parkway, Suite 400 Brisbane, California 94005 United States | |
| Phone | 415 798 8589 |
| Website | tempesttx.com |
Stock Details
| Ticker Symbol | TPST |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001544227 |
| CUSIP Number | 87978U108 |
| ISIN Number | US87978U1088 |
| Employer ID | 45-1472564 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Stephen R. Brady J.D., LLM | Chief Executive Officer, President and Director |
| Nicholas Maestas | Chief Financial Officer, Head of Corporate Strategy and Secretary |
| Dr. Samuel Whiting M.D., Ph.D. | Executive Vice President, Chief Medical Officer and Head of Research & Development |
| Justin Trojanowski CPA | Corporate Controller, Treasurer and Principal Accounting Officer |
| Lindsay Young | Head of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 30, 2025 | 10-K/A | [Amend] Annual report |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 18, 2025 | 8-K | Current Report |
| Apr 9, 2025 | 8-K | Current Report |
| Apr 7, 2025 | 8-K | Current Report |
| Mar 27, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 27, 2025 | 10-K | Annual Report |
| Mar 27, 2025 | 8-K | Current Report |
| Feb 11, 2025 | SCHEDULE 13D/A | Filing |
| Feb 6, 2025 | 424B5 | Filing |